Protalix BioTherapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.11.24	Protalix BioTherapeutics Inc. Q3 Earnings Summary (RTTNews)
14.08.24	Protalix BioTherapeutics Inc. Q2 Earnings Summary (RTTNews)
10.05.24	Protalix BioTherapeutics Inc. Q1 Loss Increases, Misses Estimates (RTTNews)
06.11.23	Protalix BioTherapeutics Inc. Q3 loss drops in line with estimates (RTTNews)
12.09.23	Protalix BioTherapeutics Appoints Eliot Richard Forster To Succeed Zeev Bronfeld As Chairman (RTTNews)
07.08.23	Protalix BioTherapeutics Inc. Q2 Earnings Summary (RTTNews)
10.05.23	Pre-market Movers: CTIC, UPST, ISIG, SFWL, CUEN… (RTTNews)
10.05.23	Chiesi Global Rare Diseases, Protalix Say ELFABRIO Approved By FDA For Fabry Disease (RTTNews)
10.05.23	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease (PR Newswire)
05.05.23	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease (PR Newswire)
04.05.23	Protalix BioTherapeutics Inc. Q1 sales decline (RTTNews)
27.04.23	Biotech Stocks That Hit New Highs Yesterday (RTTNews)
27.02.23	Protalix BioTherapeutics FY Loss Narrows - Quick Facts (RTTNews)
24.02.23	Chiesi, Protalix Receive Positive CHMP Opinion For Pegunigalsidase Alfa To Treat Fabry Disease (RTTNews)
24.02.23	Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease (PR Newswire)
05.12.22	Protalix, Chiesi: FDA Accepts Resubmitted BLA For Pegunigalsidase Alfa To Treat Fabry Disease (RTTNews)
14.11.22	Protalix BioTherapeutics Posts Narrower Loss In Q3 - Quick Facts (RTTNews)
14.11.22	Protalix Resubmits To FDA The BLA For Pegunigalsidase Alfa For Treatment Of Fabry Disease (RTTNews)
15.08.22	Protalix BioTherapeutics Inc. Q2 Loss Narrows (RTTNews)
16.05.22	Protalix BioTherapeutics Inc. Q1 Loss decreases, but misses estimates (RTTNews)
04.04.22	Protalix BioTherapeutics Reports Positive Topline Results From BALANCE Phase III Trial (RTTNews)
18.03.22	Protalix Announces Positive Late-stage Study Results For PRX-102 To Treat Fabry Disease (RTTNews)
28.02.22	Protalix Submits Marketing Authorization Application To EMA For PRX-102 For Fabry Disease Treatment (RTTNews)
15.11.21	Protalix BioTherapeutics Inc. Q3 Earnings Summary (RTTNews)
11.10.21	Protalix Says Potential Pathway For Resubmission Of PRX-102 BLA On Fabry Disease Treatment (RTTNews)
16.08.21	Protalix BioTherapeutics Inc. Q2 Earnings Summary (RTTNews)
02.06.21	Protalix, Chiesi Global Announce Topline Results From The Interim Analysis Of Balance Study (RTTNews)
14.05.21	EARNINGS SUMMARY: Details of Protalix BioTherapeutics Inc. Q1 Earnings Report (RTTNews)
14.05.21	EARNINGS SUMMARY: Details of Protalix BioTherapeutics Inc. Q1 Earnings Report (RTTNews)
28.04.21	Protalix Receives Complete Response Letter Regarding BLA For PRX-102 - Quick Facts (RTTNews)
27.03.21	Biotech Stocks Facing FDA Decision In April 2021 (RTTNews)
30.12.20	Protalix BioTherapeutics Seeks Multiple Collaborative Partnerships To Complement Core Platform (RTTNews)
30.12.20	Protalix & Chiesi: Phase III BRIDGE Trial Evaluating Pegunigalsidase Alfa Meets Key Objectives (RTTNews)
27.11.20	Protalix: FDA Extends PDUFA Action Date For Pegunigalsidase Alfa - Quick Facts (RTTNews)
10.08.20	EARNINGS SUMMARY: Details of Protalix BioTherapeutics Inc. Q2 Earnings Report (RTTNews)
28.05.20	Protalix Submits BLA To FDA For Pegunigalsidase Alfa For Treatment Of Fabry Disease (RTTNews)
11.05.20	Protalix: Phase III BRIDGE Switch-over Trial With PRX-102 Meets Main Objectives (RTTNews)
12.03.20	EARNINGS SUMMARY: Details of Protalix BioTherapeutics Inc. Q4 Earnings Report (RTTNews)
10.12.19	APTO On The Move, PLX To Effect Reverse Split, SCYX Plunges (RTTNews)
07.11.19	EARNINGS SUMMARY: Details of Protalix BioTherapeutics Inc. Q3 Earnings Report (RTTNews)
08.08.19	EARNINGS SUMMARY: Details of Protalix BioTherapeutics Inc. Q2 Earnings Report (RTTNews)
06.05.19	EARNINGS SUMMARY: Details of Protalix BioTherapeutics Inc. Q1 Earnings Report (RTTNews)
02.02.19	Week Ahead In Pharmaceuticals: 6 Stocks To Watch (EOLS, AVRO, SGMO...) (RTTNews)
28.01.19	What's Making News In These Pharma And Cannabis Stocks Today? (RTTNews)
07.11.18	EARNINGS SUMMARY: Details of Protalix BioTherapeutics Inc. Q3 Earnings Report (RTTNews)
09.08.18	EARNINGS SUMMARY: Details of Protalix BioTherapeutics Inc. Q2 Earnings Report (RTTNews)
05.06.18	Protalix Reports Positive Results From Final Analysis Of OPRX-106 Trial (RTTNews)
03.06.18	An Ear To The Pharma: 9 Stocks To Watch (CTMX, ZEAL, MRSN...) (RTTNews)
09.05.18	EARNINGS SUMMARY: Details of Protalix BioTherapeutics Inc. Q1 Earnings Report (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	121.15	2.19 %	K V
Logitech Intl	72.20	1.66 %	K V
Lonza Grp	526.60	1.00 %	K V
Swiss Re	129.35	0.82 %	K V
UBS Group	28.35	0.18 %	K V
Givaudan	3’901.00	-0.81 %	K V
Swiss Life Hldg	725.40	-1.12 %	K V
Holcim	89.78	-1.12 %	K V
Novartis	91.93	-1.87 %	K V
Sonova Hldg	306.20	-1.89 %	K V

Nachrichten zu Protalix BioTherapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten